Chatzikonstantinou, T. and Vasilopoulou, M. and Kyrou, D. and Karakatsoulis, G. and Argyropaidas, P. and Besikli-Dimou, S. and Bonotis, P. and Chatzimina, M. and Didi, J. and Dimosthenous, C. and Garani-Papadatos, T. and Hoffman, S. and Kakalou, C. and Kazantzaki, E. and Kiefer, S. and Koumakis, L. and Ling, J. and Maramis, C. and Meyerheim, M. and Payne, C. and Papangelou, C. and Payne, S. and Pontikoglou, C. and Reston, R. and Ryblom, H. and Sander, A. and Schera, F. and Smedby, K.E. and Zacharioudakis, G. and Chatzidimitriou, A. and Doubek, M. and Stavroyianni, N. and Ghia, P. and Papadaki, H.A. and Rosenquist, R. and Graf, N. and Natsiavas, P. and Stamatopoulos, K. and Karamanidou, C. and Scarfò, L. (2025) Assessing an eHealth Intervention on Quality of Life in Patients with Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes : The MyPal Randomized Controlled Trial. JCO Oncology Practice: OP-25-0008.
Full text not available from this repository.Abstract
PURPOSEThe MyPal study (ClinicalTrials.gov identifier: NCT04370457) is a randomized controlled clinical trial assessing an eHealth intervention on the quality of life (QoL) of patients with chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).METHODSPatients who were receiving or had previously received treatment for CLL or MDS were randomly assigned (1:1) to access the MyPal digital health platform versus standard of care. The MyPal platform included a smartphone application used to report QoL status and symptoms via standardized questionnaires or spontaneous reporting. The primary end point was QoL at 12 months, assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 General Questionnaire and the EuroQol EQ-5D-3L. Secondary end points included physical and emotional functioning, measured by the Integrated Palliative Care Outcome Scale (IPOS) scale, satisfaction with care, measured by the EORTC PATSAT-C33, and overall survival (OS). Additionally, the Edmonton Symptom Assessment System (ESAS), Brief Pain Inventory (BPI), and Emotion Thermometers (ET) QoL questionnaires were assessed only in the intervention group.RESULTSA total of 171 patients (97 and 74 in the control and intervention arms, respectively) who answered multiple questionnaires were analyzed. The intervention group reported a significant decrease in pain (β2 = -0.48 [-0.77 to -0.19], P